EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma

Navid Sobhani iD, Matteo Pittacolo iD, Alberto D'Angelo iD, Giovanni Marchegiani

Cancers · 19.02.2025 · 17 (4) · 704

DOI: 10.3390/cancers17040704 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 19.02.2025. Verfasst von Navid Sobhani und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer, able to thrive in a challenging tumor microenvironment. Current standard therapies, including surgery, radiation, chemotherapy, and chemoradiation, have shown a dismal survival prognosis, resulting in less than a year of life in the metastatic setting.

Methods

The pressing need to find better therapeutic methods brought about the discovery of new targeted therapies against the infamous KRAS mutations, the major oncological drivers of PDAC.

Results

The most common KRAS mutation is KRASG12D, which causes a conformational change in the protein that constitutively activates downstream signaling pathways driving cancer hallmarks. Novel anti-KRASG12D therapies have been developed for solid-organ tumors, including small compounds, pan-RAS inhibitors, protease inhibitors, chimeric T cell receptors, and therapeutic vaccines.

Conclusions

This comprehensive review summarizes current knowledge on the biology of KRAS-driven PDAC, the latest therapeutic options that have been experimentally validated, and developments in ongoing clinical trials.

Schlagwörter

Stichwörter der Autor:innen

KRASG12DPDACtargeted therapiestumor microenvironment

Autor:innen und Institutionen

  • Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Surgery, Oncology and Gastroenterology, University of Padova, 35122 Padova, Italy.
  • Department of Medicine, Northern General Hospital, Sheffield S5 7AT, UK.

ORCID-Profile: Navid Sobhani, Matteo Pittacolo, Alberto D'Angelo

Zitieren

APA

Sobhani, N., Pittacolo, M., D'Angelo, A., & Marchegiani, G. (2025). Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma. Cancers, 17(4), 704. https://doi.org/10.3390/cancers17040704

Vancouver

Sobhani N, Pittacolo M, D'Angelo A, Marchegiani G. Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma. Cancers. 2025;17(4):704. doi:10.3390/cancers17040704

BibTeX
@article{Sobhani2025,
  author = {Sobhani, Navid and Pittacolo, Matteo and D'Angelo, Alberto and Marchegiani, Giovanni},
  title = {Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {4},
  pages = {704},
  doi = {10.3390/cancers17040704}
}
Kostenlos starten →